Franklin Resources Inc. Buys 18,452 Shares of TG Therapeutics, Inc. $TGTX

Franklin Resources Inc. boosted its stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 25.3% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 91,387 shares of the biopharmaceutical company’s stock after acquiring an additional 18,452 shares during the quarter. Franklin Resources Inc. owned 0.06% of TG Therapeutics worth $3,289,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Wellington Management Group LLP boosted its stake in shares of TG Therapeutics by 1,809.9% during the first quarter. Wellington Management Group LLP now owns 1,213,039 shares of the biopharmaceutical company’s stock valued at $47,830,000 after purchasing an additional 1,149,526 shares during the period. Driehaus Capital Management LLC purchased a new stake in TG Therapeutics during the 1st quarter valued at $30,545,000. Nuveen LLC bought a new stake in TG Therapeutics in the 1st quarter worth $29,442,000. Woodline Partners LP purchased a new position in shares of TG Therapeutics in the first quarter valued at about $21,021,000. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its position in shares of TG Therapeutics by 1,221.4% in the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 422,078 shares of the biopharmaceutical company’s stock valued at $15,191,000 after acquiring an additional 390,137 shares during the period. Institutional investors own 58.58% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on TGTX shares. Weiss Ratings reissued a “hold (c+)” rating on shares of TG Therapeutics in a research note on Monday. JPMorgan Chase & Co. increased their price objective on TG Therapeutics from $46.00 to $49.00 and gave the stock an “overweight” rating in a report on Monday, November 3rd. HC Wainwright started coverage on TG Therapeutics in a research note on Monday, October 6th. They set a “buy” rating and a $60.00 target price on the stock. B. Riley upgraded TG Therapeutics to a “strong-buy” rating in a report on Tuesday, November 4th. Finally, Wall Street Zen upgraded shares of TG Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and two have given a Hold rating to the company. According to MarketBeat, TG Therapeutics has an average rating of “Moderate Buy” and an average price target of $50.25.

Insider Transactions at TG Therapeutics

In other news, Director Yann Echelard sold 5,000 shares of TG Therapeutics stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $32.57, for a total transaction of $162,850.00. Following the completion of the transaction, the director directly owned 223,816 shares in the company, valued at approximately $7,289,687.12. This trade represents a 2.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Sagar Lonial sold 20,852 shares of the business’s stock in a transaction that occurred on Thursday, September 11th. The stock was sold at an average price of $32.24, for a total value of $672,268.48. Following the completion of the sale, the director directly owned 94,061 shares in the company, valued at approximately $3,032,526.64. This represents a 18.15% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 10.64% of the stock is owned by corporate insiders.

TG Therapeutics Stock Down 3.3%

Shares of NASDAQ:TGTX opened at $30.63 on Wednesday. The firm has a market capitalization of $4.86 billion, a P/E ratio of 82.78 and a beta of 1.95. The company has a debt-to-equity ratio of 0.89, a quick ratio of 2.96 and a current ratio of 3.86. The stock has a 50 day moving average price of $33.70 and a 200-day moving average price of $33.87. TG Therapeutics, Inc. has a 52-week low of $25.28 and a 52-week high of $46.48.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings results on Monday, November 3rd. The biopharmaceutical company reported $2.43 earnings per share for the quarter, beating the consensus estimate of $0.24 by $2.19. The company had revenue of $161.71 million for the quarter, compared to analyst estimates of $152.12 million. TG Therapeutics had a return on equity of 26.05% and a net margin of 13.31%.The firm’s revenue was up 92.7% on a year-over-year basis. During the same period in the previous year, the company posted $0.02 earnings per share. As a group, equities research analysts anticipate that TG Therapeutics, Inc. will post 0.08 EPS for the current fiscal year.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.